REFERENCES


kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell. 2010;18(6):683-95.


92. Hehlgens S, Eke I, Cordes N. Targeting FAK radiosensitizes 3-dimensional

Cotargeting MAPK and PI3K signaling with concurrent radiotherapy as a

94. Kim D, Rath O, Kolch W, Cho KH. A hidden oncogenic positive feedback

95. Javelaud D, Mauviel A. Crosstalk mechanisms between the mitogen-activated
protein kinase pathways and Smad signaling downstream of TGF-beta:

malignant melanoma in an era of newer, more effective biological agents.

The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in

resistant colorectal cancer cells to radiation through inhibition of AMPK

99. Kartal-Yandim M, Adan-Gokbulut A, Baran Y. Molecular mechanisms of

100. Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B. The

101. Easwaran H, Tsai HC, Baylin SB. Cancer epigenetics: tumor heterogeneity,


115


188. Smalley KS, Haass NK, Brafford PA, Lioni M, Flaherty KT, Herlyn M. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther. 2006;5(5):1136-44.


